PTC Therapeutics (NASDAQ:PTCT) Price Target Raised to $82.00 at Royal Bank Of Canada

PTC Therapeutics (NASDAQ:PTCT) had its target price increased by Royal Bank Of Canada from $81.00 to $82.00 in a research report released on Friday morning,Benzinga reports. The brokerage currently has a sector perform rating on the biopharmaceutical company’s stock.

Several other research firms have also commented on PTCT. TD Cowen upgraded shares of PTC Therapeutics from a “hold” rating to a “buy” rating and increased their price objective for the company from $75.00 to $90.00 in a research report on Friday. Wells Fargo & Company increased their price objective on shares of PTC Therapeutics from $86.00 to $95.00 and gave the company an “overweight” rating in a research report on Friday. Wall Street Zen lowered shares of PTC Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, February 21st. Truist Financial upgraded shares of PTC Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 25th. Finally, Jefferies Financial Group lowered shares of PTC Therapeutics from a “buy” rating to a “hold” rating and lowered their price objective for the company from $91.00 to $76.00 in a research report on Monday, March 30th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, PTC Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $88.36.

PTC Therapeutics Price Performance

Shares of NASDAQ PTCT opened at $73.69 on Friday. The firm has a fifty day moving average price of $67.69 and a 200-day moving average price of $72.07. The stock has a market cap of $6.11 billion, a PE ratio of -31.63 and a beta of 0.53. PTC Therapeutics has a 1 year low of $43.17 and a 1 year high of $87.50.

PTC Therapeutics (NASDAQ:PTCT) last issued its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.03) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.42. PTC Therapeutics had a negative net margin of 22.58% and a negative return on equity of 362.45%. The firm had revenue of $272.55 million during the quarter, compared to analyst estimates of $217.42 million. During the same quarter in the prior year, the business earned $10.04 earnings per share. PTC Therapeutics’s revenue for the quarter was up 43.5% on a year-over-year basis. On average, research analysts expect that PTC Therapeutics will post -1.1 EPS for the current year.

Insider Activity at PTC Therapeutics

In other PTC Therapeutics news, Director Stephanie Okey sold 15,167 shares of the firm’s stock in a transaction dated Tuesday, March 10th. The shares were sold at an average price of $70.00, for a total transaction of $1,061,690.00. Following the transaction, the director owned 8,000 shares of the company’s stock, valued at approximately $560,000. This trade represents a 65.47% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Matthew B. Klein sold 2,850 shares of the firm’s stock in a transaction dated Tuesday, April 21st. The shares were sold at an average price of $70.91, for a total transaction of $202,093.50. Following the transaction, the chief executive officer directly owned 394,070 shares in the company, valued at $27,943,503.70. This trade represents a 0.72% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 126,492 shares of company stock worth $8,634,621 over the last ninety days. 5.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of PTCT. Jefferies Financial Group Inc. purchased a new position in shares of PTC Therapeutics in the 3rd quarter worth approximately $97,252,000. Janus Henderson Group PLC grew its position in shares of PTC Therapeutics by 28.6% in the 4th quarter. Janus Henderson Group PLC now owns 4,851,332 shares of the biopharmaceutical company’s stock worth $368,587,000 after buying an additional 1,077,776 shares during the last quarter. State Street Corp grew its position in shares of PTC Therapeutics by 34.2% in the 4th quarter. State Street Corp now owns 4,206,126 shares of the biopharmaceutical company’s stock worth $319,497,000 after buying an additional 1,071,343 shares during the last quarter. Toronto Dominion Bank grew its position in shares of PTC Therapeutics by 27.5% in the 4th quarter. Toronto Dominion Bank now owns 4,138,215 shares of the biopharmaceutical company’s stock worth $314,339,000 after buying an additional 891,690 shares during the last quarter. Finally, BNP Paribas Financial Markets grew its position in shares of PTC Therapeutics by 4,013.1% in the 4th quarter. BNP Paribas Financial Markets now owns 828,662 shares of the biopharmaceutical company’s stock worth $62,945,000 after buying an additional 808,515 shares during the last quarter.

Key PTC Therapeutics News

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: PTC Therapeutics reported Q1 revenue of $273 million and EPS of -$0.03, beating Wall Street estimates on both the top and bottom line. Revenue was up 43.5% year over year, and the company said its updated results support a higher full-year 2026 outlook. PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
• Positive Sentiment: The company raised FY 2026 revenue guidance to $1.1 billion-$1.2 billion, above the market’s prior expectation of about $1.0 billion, signaling stronger commercial momentum. PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
• Positive Sentiment: Wells Fargo lifted its price target on PTCT from $86 to $95 and kept an Overweight rating, suggesting further upside if execution continues. Benzinga report on Wells Fargo price target increase
• Neutral Sentiment: Royal Bank of Canada raised its price target from $81 to $82 while maintaining a Sector Perform rating, indicating a more measured view than Wells Fargo despite still acknowledging some upside. Benzinga report on RBC price target increase
• Neutral Sentiment: Management also highlighted progress in its pipeline and programs, including Sephience launch growth and positive interim data for votoplam, which may support longer-term sentiment but is less immediately impactful than the earnings beat. PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.